RBRukhmi Bhat

Rukhmi Bhat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rukhmi Bhat has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism

    by Marisol Betensky, Muayad Azzam, Rachel Sara Bercovitz, Rukhmi V. Bhat, Tina T Biss, Brian Re Branchford, Leonardo R. Brandão, Anthony K. C. Chan, E. Vincent S. Faustino, Qais Hamarsha, et al.

    Background: Venous thromboembolism (VTE) is a significant cause of morbidity in children, particularly among hospitalized patients and those with chronic medical conditions. There is a lack of consensus on anticoagulant prophylaxis strategies. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients and health care professionals in decisions about anticoagulant prophylaxis for pediatric VTE prevention. Methods: ASH formed a multidisciplinary guideline panel that included 1 patient representative. The University of Kansas Health System supported the guideline development process, including systematic evidence reviews up to April 2025. Clinical questions and outcomes were prioritized according to their importance for clinicians and patients. The panel used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to assess certainty in the evidence and make recommendations. Results: The panel agreed on 12 recommendations. For pediatric patients with solid cancer, who have experienced trauma, or who are critically ill, the panel issued conditional recommendations suggesting no anticoagulant prophylaxis. For pediatric patients with antiphospholipid antibody syndrome, or those on long-term total parenteral nutrition, the panel issued conditional recommendations suggesting the use of anticoagulant prophylaxis. Other pediatric subgroups addressed included patients with acute lymphoblastic leukemia or lymphoma, surgical and hospitalized patients, and those with a central venous access device. Conclusions: High-quality data on anticoagulant prophylaxis for pediatric VTE prevention are scarce. Key research priorities include the development and validation of subgroups-specific VTE risk assessment models, and evaluation of the safety and efficacy of risk-stratified anticoagulant prophylaxis strategies across different pediatric subgroups.


  • An international survey on current practices of management of neonatal catheter-associated venous thromboembolism: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis

    by Rukhmi Bhat, Chris V. Hulzebos, Assaf Barg, Kisha Beg, Mihir Bhatt, Anthony K.C. Chan, E. Vincent S. Faustino, Susanne Holzhauer, Sophie Jones, Ronny Knol, et al.


  • Frequency of, and prognostic factors for, residual thrombosis and complete veno-occlusion following anticoagulation for provoked venous thromboembolism in patients <21 years: findings from the Kids-DOTT Multinational Trial

    by Rukhmi Bhat, Anjali Sharathkumar, Riten Kumar, Fernando F. Corrales-Medina, Heleen van Ommen, Mihir Bhatt, Smita Dandekar, Maua Mosha, Neil A. Goldenberg

  • Open Access

    How I treat pediatric venous thromboembolism in the DOAC era

    by Rukhmi V. Bhat, Guy Young, Anjali A. Sharathkumar

    The direct oral anticoagulants (DOACs) rivaroxaban and dabigatran are newly licensed for the treatment and prevention of venous thromboembolism (VTE) in children and mark a renaissance in pediatric anticoagulation management. They provide a convenient option over standard-of-care anticoagulants (heparins, fondaparinux, and vitamin K antagonists) because of their oral route of administration, child-friendly formulations, and significant reduction in monitoring. However, limitations related to therapeutic monitoring when needed and the lack of approved reversal agents for DOACs in children raise some safety concerns. There is accumulating experience of safety and efficacy of DOACs in adults for a broad scope of indications; however, the cumulative experience of using DOACs in pediatrics, specifically for those with coexisting chronic illnesses, is sparse. Consequently, clinicians must often rely on their experience for treating VTE and extrapolate from data in adults while using DOACs in children. In this article, the authors share their experience of managing 4 scenarios that hematologists are likely to encounter in their day-to-day practice. Topics addressed include (1) appropriateness of indication; (2) use for special populations of children; (3) considerations for laboratory monitoring; (4) transition between anticoagulants; (5) major drug interactions; (6) perioperative management; and (7) anticoagulation reversal.


  • Open Access

    Intravenous fluid therapy and hospital outcomes for vaso‐occlusive episodes in children, adolescents, and young adults with sickle cell disease

    by Abraham Haimed, Rebecca Weiss, Soyang Kwon, Rukhmi Bhat, Sherif M. Badawy

    Background: While intravenous fluid (IVF) therapy in patients with sickle cell disease (SCD) admitted for a vaso‐occlusive episode (VOE) can help reduce red blood cell sickling, clinical practice varies across institutions. We examined the relationship between IVF therapy and hospital length of stay (HLOS), as well as adverse events, such as acute chest syndrome (ACS), pediatric intensive care unit (PICU) transfer, and 28‐day re‐admission.Methods: This is a single‐center retrospective analysis of SCD VOE hospitalizations between January 2015 and April 2020. Patients with SCD, age 0–30, with consecutive hospitalizations for VOE were included. For the first 3 days of each admission, an “IVF ratio” was calculated by dividing actual IVF rate administered by weight‐based maintenance IVF (mIVF) rate.Results: A total of 617 hospitalizations for 161 patients were included. Mean HLOS was 5.7 days, (SD 3.9), and mean IVF volume over the first 3 days of admission was 139.6 mL/kg/day (SD 57.8). Multivariate analysis showed that for each additional 0.5 times the mIVF rate, HLOS increased by 0.53 day (p < .001; 95% confidence interval [CI]: 0.609–0.989), but there was no significant association between IVF therapy and adverse events. History of chronic pain was associated with increased odds of re‐admission (OR 6.4; 95% CI: 3.93–10.52).Conclusions: Despite the theoretical potential for IVF therapy to slow down the sickling process, our findings suggest that increased IVF therapy was associated with prolonged HLOS, which places a burden on patients, families, and the health system.


  • Open Access

    Intravenous Fluid Therapy and Hospital Outcomes for Vaso-Occlusive Episodes in Children, Adolescents, and Young Adults with Sickle Cell Disease

    by Abraham Haimed, Rebecca Weiss, Soyang Kwon, Rukhmi Bhat, Sherif Badawy

    Background: While intravenous fluid (IVF) therapy in patients with sickle cell disease (SCD) admitted for a vaso-occlusive episodes (VOE) can help reduce red blood cell sickling, clinical practice varies across institutions. We examined the relationship between IVF therapy and hospital length of stay (HLOS), as well as adverse events, such as acute chest syndrome (ACS), pediatric intensive care unit (PICU) transfer and 28-day readmission. Methods: This is a single-center retrospective analysis of SCD VOE hospitalizations between January 2015 and April 2020. Patients with SCD, age 0-30, with consecutive hospitalizations for VOE were included. For the first 3 days of each admission, an “IVF ratio” was calculated by dividing actual IVF rate administered by weight-based maintenance IVF (mIVF) rate. Results: A total of 617 hospitalizations for 161 patients were included. Mean HLOS was 5.7 days, (SD 3.9), and mean IVF volume over the first 3 days of admission was 139.6 ml/kg/day (SD 57.8). Multivariate analysis showed that for each additional 0.5 times the mIVF rate, HLOS increased by 0.53 days (PConclusions: Despite the theoretical potential for IVF therapy to slow down the sickling process, our findings suggest that increased IVF therapy was associated with prolonged HLOS, which places a burden on patients, families, and the health system.

  • Risk factors for neonatal thrombosis

    by Rukhmi Bhat, Robert I Liem

  • Early thrombotic and hemorrhagic complications associated with a risk‐adjusted postoperative anticoagulation protocol after pediatric liver transplantation

    by Caroline P. Lemoine, Katherine A. Brandt, Saeed Mohammad, Rukhmi Bhat, Riccardo Superina

    Background: Systemic anticoagulation after pediatric liver transplantation (pLT) is believed to reduce the incidence of vascular thrombosis, but it may also cause an increase in hemorrhagic complications.Procedure: A 5‐year retrospective review of pLT done at our institution was performed (2014–2018). The occurrence of early hemorrhagic and thrombotic complications was compared when using low‐dose or high‐dose anticoagulation after transplant (p < .05 considered significant).Results: Sixty‐nine patients received 73 transplants during the study period. Median age at transplant was 2.3 years (40 days to 18.5 years). Low‐dose anticoagulation was utilized in 71% cases. Additionally, six patients were converted from low‐dose to high‐dose anticoagulation because of a thrombotic event or concerns for suboptimal vascular inflow. Postoperative anticoagulation was discontinued in 18 occurrences due to bleeding (low dose 19%, high dose 47% vs. low dose to high dose 17%, p = .085). Surgical take back for bleeding occurred in 17 occasions (low dose 13.5%, high dose 53% vs. low dose to high dose 33%, p = .005). The overall incidence of hepatic artery thrombosis (HAT) and portal vein thrombosis were each 5.5%, respectively. While patient survival was not statistically different between groups, graft survival was significantly lower in the high‐dose group (low dose 93%, high dose 73% vs. low dose to high dose 100%, p = .046). However, graft losses from HAT were similar between groups (low dose 2%, high dose 7% vs. low dose to high dose 0%, p = .56).Conclusion: The use of a standardized risk‐adjusted anticoagulation protocol after pLT is associated with a low occurrence of thrombotic and hemorrhagic complications. High‐dose anticoagulation leads to more bleeding, but those risks outweigh the risks of possible graft loss.


  • A case of severe bi‐cytopenias and hypocellular bone marrow with uncontrolled nephropathic cystinosis

    by Sherif M. Badawy, Alisa Vasileva, Rukhmi V. Bhat, Shunyou Gong, Robert I. Liem